RhumbLine Advisers’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.6M | Sell |
122,394
-9,366
| -7% | -$199K | ﹤0.01% | 1745 |
|
|
2025
Q1 | $2.54M | Buy |
131,760
+6,558
| +5% | +$127K | ﹤0.01% | 1696 |
|
|
2024
Q4 | $2.23M | Buy |
125,202
+5,394
| +5% | +$96.3K | ﹤0.01% | 1831 |
|
|
2024
Q3 | $2.62M | Sell |
119,808
-8,811
| -7% | -$193K | ﹤0.01% | 1749 |
|
|
2024
Q2 | $1M | Sell |
128,619
-12,024
| -9% | -$93.8K | ﹤0.01% | 2243 |
|
|
2024
Q1 | $582K | Buy |
140,643
+6,932
| +5% | +$28.7K | ﹤0.01% | 2570 |
|
|
2023
Q4 | $349K | Buy |
133,711
+424
| +0.3% | +$1.11K | ﹤0.01% | 2877 |
|
|
2023
Q3 | $249K | Buy |
133,287
+6,061
| +5% | +$11.3K | ﹤0.01% | 3035 |
|
|
2023
Q2 | $319K | Buy |
+127,226
| New | +$319K | ﹤0.01% | 2968 |
|
|
2022
Q2 | – | Sell |
-15,115
| Closed | -$37K | – | 3221 |
|
|
2022
Q1 | $37K | Buy |
15,115
+2,292
| +18% | +$5.61K | ﹤0.01% | 2988 |
|
|
2021
Q4 | $34K | Sell |
12,823
-603
| -4% | -$1.6K | ﹤0.01% | 2994 |
|
|
2021
Q3 | $67K | Buy |
13,426
+908
| +7% | +$4.53K | ﹤0.01% | 3015 |
|
|
2021
Q2 | $93K | Buy |
+12,518
| New | +$93K | ﹤0.01% | 2970 |
|